Biomarkers of prognosis and pazopanib response in soft tissue sarcoma: An exploratory analysis
Jose L. Mondaza-Hernandez,
Ruben Amian-Ruiz,
Juan Antonio Cordero Varela,
Maria Augusta Carrera-Haro,
María Celeste Rodriguez,
Maria Lopez-Alvarez,
Victor H. Villar,
Rafa Ramos,
Claudia Valverde,
Josefina Cruz,
Javier Martinez-Trufero,
Roberto Diaz-Beveridge,
Nadia Hindi,
Antonio Fernandez-Serra,
Jose A. Lopez-Guerrero,
David S. Moura,
Javier Martin-Broto,
Group of Advanced Therapies and Biomarkers in Sarcoma,
Research Health Institute of Fundación Jiménez Díaz ,
Medical Oncology Department,
University Hospital General of Villalba,
Molecular Biology of Cancer,
Instituto de Biomedicina de Sevilla ,
Hospital Universitario Virgen del Rocío ,
Universidad de Sevilla,
School of Medicine,
University of St Andrews,
St Andrews,
Department of Pathology,
Hospital Universitari Son Espases,
Department of Medical Oncology,
Vall d,
Hebron University Hospital,
Department of Medical Oncology,
Hospital Universitario de Canarias,
La Laguna,
Department of Medical Oncology,
Hospital Universitario Miguel Servet,
Department of Medical Oncology,
La Fe University and Polytechnic Hospital,
Department of Medical Oncology,
Fundación Jiménez Díaz University Hospital,
Molecular Biology Laboratory,
Instituto Valenciano de Oncología
Therapeutic Advances in Medical Oncology
Published online on August 01, 2026
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
BackgroundAdvanced soft tissue sarcoma (STS) is a group of rare and heterogeneous malignancies, requiring better therapeutic strategies. Pazopanib, a widely used second-line treatment, has been suggested to exert immunomodulatory effects, which may be ...